Oral Beeswax Beta-Sitosterol Composition for Fibroblast Regulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for fibrosis and scar formation are inadequate in regulating fibroblast growth and proliferation, leading to excessive and persistent tissue damage, as existing methods fail to effectively inhibit the activation and proliferation of ECM-producing cells, such as fibroblasts, which are central to the fibrosis process.
Innovation Solution
A pharmaceutical composition comprising a homogenous mixture of edible oil, beeswax, and β-sitosterol, where the beeswax forms microcrystals, is used for oral administration to inhibit fibroblast growth and activation, thereby addressing the core issue of fibrosis and scar formation by regulating fibroblast metabolism and proliferation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatment methods are used for fibrosis, then general tissue protection is achieved, but fibroblast growth and proliferation are not effectively regulated
Solution Approach 1:
The patent changes the chemical composition parameters by incorporating β-sitosterol (0.1-20% w/w) and beeswax (5-50% w/w) in specific ratios, which fundamentally alters the composition's interaction with fibroblasts. This parameter change enables the composition to specifically regulate fibroblast proliferation and activation, resolving the contradiction between general treatment reliability and specific fibroblast growth regulation capability.
Solution Approach 2:
The patent creates a composite material system combining edible oil, beeswax, and β-sitosterol in specific proportions. This composite material works synergistically to protect mucosal tissues while simultaneously regulating fibroblast growth. The composite nature allows the composition to achieve both general tissue protection and specific anti-fibrotic effects, resolving the technical contradiction.
2Productivity
If fibroblast activation is promoted for tissue repair, then wound healing is enhanced, but excessive fibrosis and scar formation occur
Solution Approach 1:
The patent employs a feedback mechanism where β-sitosterol and beeswax modulate fibroblast activation in a controlled manner. The composition stimulates initial fibroblast activity for wound healing but simultaneously provides negative feedback to prevent excessive proliferation and ECM overproduction. This feedback control resolves the contradiction between enhancing tissue repair and preventing fibrosis.
Solution Approach 2:
The patent applies partial action by using specific concentrations of β-sitosterol (0.1-20%) and beeswax (5-50%) that provide sufficient stimulation for tissue repair without causing excessive fibroblast activation. The optimized dosage range ensures adequate wound healing while avoiding the harmful effects of over-activation, thus resolving the contradiction between repair rate and fibrosis prevention.
3Device complexity
If a single active ingredient is used to treat fibrosis, then treatment simplicity is maintained, but comprehensive regulation of fibroblast functions is insufficient
Solution Approach 1:
The patent merges multiple functional components (edible oil as base, beeswax for microcrystal formation, and β-sitosterol for anti-proliferative activity) into a single integrated composition. This combination provides comprehensive fibroblast regulation including proliferation control, activation modulation, and ECM production regulation, while maintaining formulation simplicity for oral administration, thus resolving the contradiction between complexity and versatility.
Solution Approach 2:
The patent creates a multi-functional composition where the same formulation simultaneously protects mucosal tissues, regulates fibroblast proliferation, modulates fibroblast activation, and controls ECM production. This universal composition eliminates the need for multiple separate treatments, resolving the contradiction between formulation simplicity and comprehensive fibroblast function regulation.
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
An application of an oral pharmaceutical composition in manufacturing of a medication for regulating fibroblast growth and treating or preventing organ fibrosis. The pharmaceutical composition comprises a homogeneous mixture of an edible oil, beeswax, and β-sitosterol, wherein the beeswax forms microcrystals, and on the basis of the total weight of the composition, the content of the beeswax is 0.5-50% and the content of β-sitosterol is 0.1%-20%.